Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking will make prepayments totaling $150 million to CordenPharma between 2025-2028
The deal secures manufacturing capacity for both injectable and oral formulations of VK2735
Annual capacity includes:
Multiple metric tons of VK2735 active pharmaceutical ingredient (API)
100 million autoinjectors
100 million vial/syringe products
Over 1 billion oral tablets
VK2735 is Viking's dual GLP-1/GIP receptor agonist in development for obesity treatment
The agreement aims to support potential multi-billion dollar annual product opportunity
Viking retains all global rights to VK2735
CordenPharma will provide API manufacturing and fill/finish services
The deal helps Viking secure long-term supply chain for VK2735 commercialization
Viking plans to start Phase 3 trials for the injectable formulation in Q2 2025
An oral formulation is currently in Phase 2 trials
This manufacturing agreement positions Viking to compete in the fast-growing obesity drug market dominated by Novo Nordisk and Eli Lilly, while securing supply for potential future commercial demand of its promising obesity drug candidate.